HomeBAVA • CPH
add
Bavarian Nordic A/S
Previous close
kr 151.90
Day range
kr 151.90 - kr 158.05
Year range
kr 125.55 - kr 222.00
Market cap
11.86B DKK
Avg Volume
402.72K
P/E ratio
-
Dividend yield
-
Primary exchange
CPH
Market news
Financials
Income Statement
Revenue
Net income
| (DKK) | Dec 2023info | Y/Y change |
|---|---|---|
Revenue | 2.45B | 89.64% |
Operating expense | 1.24B | 68.00% |
Net income | 901.39M | 502.44% |
Net profit margin | 36.83 | 217.77% |
Earnings per share | 11.70 | 431.82% |
EBITDA | 1.06B | 283.93% |
Effective tax rate | -0.34% | — |
Balance Sheet
Total assets
Total liabilities
| (DKK) | Dec 2023info | Y/Y change |
|---|---|---|
Cash and short-term investments | 1.87B | -34.36% |
Total assets | 14.35B | 15.83% |
Total liabilities | 4.01B | -23.43% |
Total equity | 10.34B | — |
Shares outstanding | 77.94M | — |
Price to book | 1.15 | — |
Return on assets | 16.82% | — |
Return on capital | 23.43% | — |
Cash Flow
Net change in cash
| (DKK) | Dec 2023info | Y/Y change |
|---|---|---|
Net income | 901.39M | 502.44% |
Cash from operations | 585.45M | 169.23% |
Cash from investing | -143.72M | 75.50% |
Cash from financing | 13.22M | -94.28% |
Net change in cash | 445.05M | 410.71% |
Free cash flow | -743.59M | 36.06% |
About
Bavarian Nordic A/S is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with a manufacturing facility in Kvistgård, and an additional site in Hørsholm. The company has a research and development facility in Martinsried, Germany, and offices in Zug, Switzerland, and Morrisville, North Carolina. The company uses viral vectors in its research and development. Wikipedia
CEO
Founded
Jul 1, 1992
Website
Employees
1,379
